Groups representing the biopharma industry have welcomed an increase in health-specific R&D to £5 billion in the UK autumn budget, despite a longer timeline for reaching the target of £
The UK's long-awaited Life Sciences Vision strategy has been published, setting out the government's stall as it tries to deliver on its promise to keep the country at the forefront of the
The UK's biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry
The UK government used the Queen's Speech to set out its ambition to make the country a leader in life sciences, garnering a warm response from industry groups.
The post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some degree of stability – but also plenty of disruption – for the coming m
In his first budget as UK chancellor, Rishi Sunak’s main focus was to prepare the country for the impact of coronavirus – but there were other pharma-friendly measures in there too.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS